EPEdwige Petit

Edwige Petit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edwige Petit has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eficácia e segurança em médio prazo e potenciais preditores de resposta ao upadacitinibe em pacientes com dermatite atópica moderada a grave: estudo retrospectivo observacional multicêntrico

    by Francisco Javier Melgosa Ramos, Carlos Abril Pérez, Santiago Guillén Climent, María Matellanes Palacios, Juncal Roca Ginés, Javier Sabater Abad, Eduardo Bernia Petit, Andrés Casanova Esquembre, Andrea Estébanez Corrales, Victor González Delgado

  • Open Access

    Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study

    by Francisco Javier Melgosa Ramos, Carlos Abril Pérez, Santiago Guillén Climent, María Matellanes Palacios, Juncal Roca Ginés, Javier Sabater Abad, Eduardo Bernia Petit, Andrés Casanova Esquembre, Andrea Estébanez Corrales, Victor González Delgado


  • Open Access

    Angiopoietin-2 is Vasoprotective in the Acute Phase of Cerebral Ischemia

    by Léna Marteau, Samuel Valable, Didier Divoux, Simon A Roussel, Omar Touzani, Eric T MacKenzie, Myriam Bernaudin, Edwige Petit

    Most forms of cerebral ischemia are characterized by damage to the entire neurovascular unit, which leads to an increase in the permeability of the blood–brain barrier (BBB). In response to permanent focal cerebral ischemia in mice, we detected an early concomitant increase in the expression of the vascular endothelial growth factor (VEGF), a key inducer of vascular leakage and pathological blood vessel growth, and of angiopoietin-2 (Ang2), which is closely associated with VEGF in vascular remodeling. Thus, the aim of this study was to evaluate the role of Ang2 alone, or in combination with VEGF, in the acute phase of cerebral ischemia. The effect of these angiogenic factors on the ischemic lesion volume was evaluated by magnetic resonance imaging. We observed that timely administration of VEGF exacerbates ischemic damage. In contrast, Ang2 decreases the ischemic volume and this beneficial effect is maintained in the presence of VEGF. This investigation reports, for the first time, a protective role of Ang2 following cerebral ischemia, an action associated with a reduced BBB permeability. We propose that Ang2 represents a pertinent molecular target for the treatment of cerebral ischemia since acute brain damage may be limited by a pharmacological protection of the vascular compartment.


  • Targeting the erythropoietin receptor on glioma cells reduces tumour growth

    by Elodie A. Pérès, Samuel Valable, Jean-Sébastien Guillamo, Léna Marteau, Jean-François Bernaudin, Simon Roussel, Emmanuèle Lechapt-Zalcman, Myriam Bernaudin, Edwige Petit


  • Open Access

    MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model

    by Samuel Valable, Dauphou Eddi, Jean-Marc Constans, Jean-Sébastien Guillamo, Myriam Bernaudin, Simon Roussel, Edwige Petit

    Despite treatment efforts, the median survival in patients with glioblastoma multiforme, the most aggressive form of glioma, does not extend beyond 12–15 months. One of the major pathophysiological characteristics of these tumors is their ability to induce active angiogenesis. Thus, based on the lack of efficient therapies, agents that inhibit angiogenesis are particularly attractive as a therapeutic option. However, it has been recently proposed that although specifically targeting vascular endothelial growth factor, the main angiogenic factor, certainly leads to significant tumor regression, it could also be followed by tumor relapses. In this case, angiogenesis is driven by alternate pathways that include other angiogenic factors. One possible strategy to overcome this therapeutic obstacle is to overexpress antivascular factors such as angiopoietin-2 (Ang2). Here, by using MRI and histological analysis, we studied the vascular events involved in glioma growth impairment induced by Ang2 overexpression. Our results show that an increase in Ang2 expression, during the tumor growth, leads to a significant decrease in tumor growth (∼86%) along with an increase in the survival median (∼70%) but does not modify the tumor vascular area or cerebral blood volume. However, tumor Ang2-derived blood vessels display an abnormal, enlarged morphology. We show that the presence of Ang2 leads to an enhancement of tumor perfusion and a decrease in tumor vessel permeability. Based on our MR image evaluations of hemodynamic tumor vessel changes, we propose that Ang2-derived tumor vessels lead to an inadequate oxygenation of the tumor tissue, leading to impairment in tumor growth.


  • Open Access

    Endogenous Erythropoietin as Part of the Cytokine Network in the Pathogenesis of Experimental Autoimmune Encephalomyelitis

    by Manuela Mengozzi, Ilaria Cervellini, Paolo Bigini, Sara Martone, Antonella Biondi, Rosetta Pedotti, Barbara Gallo, Sara Barbera, Tiziana Mennini, Mariaserena Boraso, et al.

    Erythropoietin (EPO) is of great interest as a therapy for many of the central nervous system (CNS) diseases and its administration is protective in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Endogenous EPO is induced by hypoxic/ischemic injury, but little is known about its expression in other CNS diseases. We report here that EPO expression in the spinal cord is induced in mouse models of chronic or relapsing-remitting EAE, and is prominently localized to motoneurons. We found a parallel increase of hypoxia-inducible transcription factor (HIF)-1 alpha, but not HIF-2 alpha, at the mRNA level, suggesting a possible role of non-hypoxic factors in EPO induction. EPO mRNA in the spinal cord was co-expressed with interferon (IFN)-gamma and tumor necrosis factor (TNF), and these cytokines inhibited EPO production in vitro in both neuronal and glial cells. Given the known inhibitory effect of EPO on neuroinflammation, our study indicates that EPO should be viewed as part of the inflammatory/anti-inflammatory network in MS.


  • Erythropoietin, a Cytoprotective and Regenerative Cytokine, and the Hypoxic Brain

    by Emilie Pacary, Edwige Petit, Myriam Bernaudin

    Hypoxia and ischemia in the brain often result in brain dysfunctions and neuronal death during both the neonatal and adult periods. Though the mechanisms contributing to brain injury secondary to hypoxia-ischemia are more clearly defined, there are still no pharmacological treatments available to reduce cell death in the ischemic brain. This review highlights the beneficial effects of hypoxia-inducible factors, such as the transcriptional factor hypoxia-inducible factor-1 and its target genes, as both cytoprotective and regenerative factors, and focuses in particular on one of the most well-known: erythropoietin. Altogether, the data presented in this review suggest that further insights into the role of hypoxia-inducible factors would help develop promising strategies to improve the outcome of hypoxia/ischemia-related brain pathologies.